Detalhe da pesquisa
1.
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS).
Cancer
; 127(23): 4421-4431, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34424530
2.
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
J Clin Oncol
; 23(17): 3923-31, 2005 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-15897550
3.
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.
Clin Cancer Res
; 9(10 Pt 1): 3578-88, 2003 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-14506144
4.
Histone deacetylase inhibitors: development as cancer therapy.
Novartis Found Symp
; 259: 269-81; discussion 281-8, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-15171260
5.
Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.
J Clin Oncol
; 28(2): 285-91, 2010 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-19933907
6.
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.
Invest New Drugs
; 26(1): 81-7, 2008 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17960324
7.
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
Blood
; 109(1): 31-9, 2007 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16960145